| Xia Meng |
Xia Meng is currently the Head-Early Diagnosis & Intervention at AbelZeta Pharma, Inc. Prior to this, Dr. Meng held positions as the Head-Institute Merieux Laboratory at Fudan University Shanghai Cancer Center, and as the General Manager at both Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. and Transgene Biopharmaceutical Technology (Shanghai) Co. Ltd. Dr. Meng completed an undergraduate degree at Wuhan University and a doctorate degree at Université Pierre et Marie Curie. |
| Yi Hong Yao |
Yi Hong Yao is currently the Chief Scientific Officer at AbelZeta Pharma, Inc. Prior to this, he worked as a Director at Medimmune, Inc. from 2011 to 2015. Dr. Yao received his graduate degree from Boston University, his doctorate from the University of Kansas, and his undergraduate degree from Fudan University. |
| Cheng Xiang Dai |
Cheng Xiang Dai currently works at AbelZeta Pharma, Inc., as General Manager-Stem Cell Business Unit. Dr. Dai also formerly worked at Venturepharma, Inc., as Medical Director. Dr. Dai received his graduate degree from Zhengzhou University. |
| Li Zhang |
Li Zhang currently works as a Chief Production Officer at AbelZeta Pharma, Inc. |
| Bi Zuo Liu |
Bi Zuo Liu is currently the Chairman, Chief Executive & Financial Officer at AbelZeta Pharma, Inc. and the Executive Director at Cellular Biomedicine Group (Shanghai) Ltd. Previously, he worked as an Accounting Director at Microsoft Corp., Vice President at Alibaba Group Holding Ltd., and Chief Financial Officer at HiChina. Mr. Liu holds an MBA from Seattle Pacific University and an undergraduate degree from Soochow University. |
| Chun Kwok Au |
Chun Kwok Au is the founder of Gt Healthcare Group, which was founded in 2015. He currently holds positions as an Independent Non-Executive Director at CSPC Pharmaceutical Group Ltd., AbelZeta Pharma, Inc., and I-Mab. He is also a Member of The American Institute of Certified Public Accountants and an Associate Member of The Hong Kong Institute of Financial Analysts & Professional. Mr. Au has held former positions as an Independent Non-Executive Director at Simcere Pharmaceutical Group Ltd., an Independent Director at China Nepstar Chain Drugstore Ltd., a Director at JAFCO Investment (Asia Pacific) Ltd., a Director at Morningside Group (Holdings) Ltd., and the Head-Asia Healthcare Investment Banking Group at Deutsche Bank AG. He was also a Partner at Ally Bridge Group HK Ltd. Mr. Au received his undergraduate degree from The Chinese University of Hong Kong in 1995 and his graduate degree from Columbia Business School in 2007. |
